The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Getting the most out of follow-up: A prospective study using the Measure of Ovarian Symptoms and Treatment concerns (MOST) symptom index to evaluate and track adverse effects (AEs) and detect symptoms of recurrence in patients with ovarian cancer (OC) following first line chemotherapy (1LT).
 
Michael Friedlander
Honoraria - AstraZeneca; MSD
Consulting or Advisory Role - AstraZeneca; MSD
Research Funding - BeiGene (Inst)
 
Madeleine King
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst)
 
Christina Nagle
No Relationships to Disclose
 
Andreas Obermair
Stock and Other Ownership Interests - SurgicalPerformance
Honoraria - Covidien
Consulting or Advisory Role - The O.R. Company
Expert Testimony - The O.R. Company
Travel, Accommodations, Expenses - The O.R. Company
 
Peter T. Grant
Research Funding - Clovis Oncology (Inst)
 
Anna deFazio
Honoraria - Roche
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst)
Patents, Royalties, Other Intellectual Property - Hold a patent related to a novel treatment target in ovarian cancer
 
Penelope M Webb
Research Funding - AstraZeneca (Inst)